News and Press Releases
Betrixaban Approved as Oral VTE PreventiveFDA and Portola Pharmaceuticals on June 23 announced the approval of betrixaban oral capsules to reduce the risk of venous thromboembolism in adults hospitalized for an acute medical illness who have restricted mobility or other risk factors for thromboembolic complications.
6/19/2017 Press Release
ASHP's Chapter <800> Answer Book Prepares Pharmacies for New Safety RequirementsASHP recently released a new reference to provide expert guidance and practical advice to pharmacists, technicians, and other health professionals involved in the compounding and handling of hazardous drugs. The Chapter Answer Book by Patricia C. Kienle, R.Ph., M.P.A., FASHP, is the first publicati
Some Hospira Products Get 'New Use Dates' While Others Get RecalledFDA on Thursday announced that certain lots of Hospira Inc.'s atropine sulfate 0.1 mg/mL injection, 50 percent dextrose injection, and epinephrine 0.1 mg/mL injection — all in syringes — have "new use dates" based on stability data provided by parent company Pfizer.
6/16/2017 Press Release
The Washington Post Names ASHP a Top Workplace for 2017ASHP (American Society of Health-System Pharmacists) has been selected as one of The Washington Post’s Top Workplaces for 2017. This marks the second consecutive year that ASHP has been named one of the Top Workplaces in the greater Washington, D.C., area.
Attention Turns to Nonpharmacy Sterile Compounding ActivitiesIn the year since investigators entered a New York City oncology clinic in search of the source of an outbreak of fungal bloodstream infections involving 17 patients, information has emerged suggesting that healthcare facilities without a pharmacy professional go unmonitored for adherence to sterile compounding standards.
Joseph A. Oddis Honored at ASHP Headquarters DedicationASHP Chief Executive Officer Emeritus Joseph A. Oddis took center stage at the ribbon-cutting and dedication ceremony for the organization's new headquarters office in Bethesda, Maryland.
New Codeine Warnings Prompt Action on NewbornsAt Baxter Regional Medical Center, a flurry of activity followed FDA's April 20 announcement of new warnings and contraindications in the labeling for codeine- and tramadol-containing products to prevent respiratory depression and other adverse events in infants and children.